Drug intelligence / Profile preview

ALT-020

Development stage: Unknown
Lead developer: Altacor
Modality: Small Molecules
Administration: Ophthalmic

Overview

**ALT-020** is an investigational antimicrobial agent developed by Altacor Ltd. for topical ophthalmic use. It is designed to treat **eye infections**, demonstrating antimicrobial efficacy in preclinical studies by reducing microbial load on the ocular surface for up to 6 hours compared to saline control. The global highest R&D status is Pending, with no detailed mechanism of action publicly disclosed.[1][5]

Beyond the preview

Go deeper on ALT-020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALT-020.

Explore the full profile